4D Molecular Therapeutics, Inc. FDMT 深 滬
已收盤 12-19 16:00:00 美东时间
8.68
-0.010
-0.12%
華盛通- 最 高9.04
- 今 開8.44
- 成交量 482.92万股
- 最 低 8.37
- 昨 收 8.69
- 總市值 4.96亿
- 52周最高 12.34
- 市盈率 靜 --
- 換手率 8.45%
- 52周最低 2.235
- 委 比 19.32%
- 總股本 5713.51万
- 歷史最高 55.11
- 量 比 3.04
- 振 幅 7.71%
- 歷史最低 2.235
- 每 手 1
- 風險率 2.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung Disease Shows Meaningful Lung Function Activity
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with
12-17 20:03
4DMT Announces New Employment Inducement Grants
4DMT, a late-stage biotechnology company, announced the grant of 13,800 Restricted Stock Units to three new non-executive employees under its 2025 Employment Inducement Award Plan. The company is focused on advancing durable and disease-targeted therapeutic candidates, such as 4D-150 for treating blinding retinal vascular diseases, and 4D-710 for cystic fibrosis. All product candidates are in clinical or preclinical development and have not yet r...
12-12 21:05
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
4D Molecular Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT. The presentation will include updates on the company's lead product candidate 4D-150, currently in Phase 3 development for wet age-related macular degeneration, and its second candidate 4D-710 for cystic fibrosis. A webcast will be available live and archived for one year on the company's investor website.
12-08 13:00
4DMT to Participate in 8th Annual Evercore Healthcare Conference
4D Molecular Therapeutics announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 2:35 p.m. ET. The company, focused on developing innovative therapeutics for blinding retinal vascular diseases and cystic fibrosis, will also offer one-on-one meetings. Its lead product, 4D-150, is in Phase 3 for wet age-related macular degeneration, and 4D-710 targets cystic fi...
11-20 13:00
4D Molecular Therapeutics taps Kristian Humer as CFO
4D Molecular Therapeutics (FDMT) has appointed Kristian Humer as chief financial officer. Humer is a seasoned finance executive and biotechnology leader with more than two decades of experience, inclu...
11-17 19:17
4DMT Appoints Kristian Humer as Chief Financial Officer
4D Molecular Therapeutics任命Kristian Humer为首席财务官，负责财务策略和运营。Humer在金融和生物技术领域拥有超过20年的经验，曾担任Citi的医疗投资银行业务负责人，并担任多家公开上市公司 CFO。此次任命正值公司推进多个III期临床项目及准备商业化之际。公司CEO David Kirn表示，Humer的专业背景将助力4DMT实现长期增长和价值最大化。Humer表示期待与团队合作，推动公司的财务和战略发展。
11-17 11:00
4DMT Announces New Employment Inducement Grants
4DMolecular Therapeutics授予四位新员工45,400个限制性股票单位，依据2025年就业激励计划。公司专注于开发治疗眼科疾病和囊性纤维化的创新疗法，产品处于临床试验阶段。
11-14 21:05
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Estimate
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.98) by 3.27 percent. This is a 27.85 percent decrease over losses of $(0.79) per
11-10 21:08
